. 2018 Sep 20;103(12):2088–2096. doi: 10.3324/haematol.2018.194282
Copyright© 2018 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:
https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:
https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.
Table 3.
Most common all grade (≥15%) and grade 3/4 (≥5%) treatment-emergent adverse events in the safety population
